<SEC-DOCUMENT>0001213900-23-032990.txt : 20230427
<SEC-HEADER>0001213900-23-032990.hdr.sgml : 20230427
<ACCEPTANCE-DATETIME>20230427070231
ACCESSION NUMBER:		0001213900-23-032990
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230427
FILED AS OF DATE:		20230427
DATE AS OF CHANGE:		20230427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences Ltd
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38723
		FILM NUMBER:		23851814

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiziana Life Sciences plc
		DATE OF NAME CHANGE:	20171116
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea177504-6k_tizianalife.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM&nbsp;6-K</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>April
2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B>&nbsp; <B>001-38723</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tiziana
Life Sciences LTD</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th</SUP>&nbsp;Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM&nbsp;6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 27, 2023, Tiziana Life Sciences LTD (the &ldquo;<U>Company</U>&rdquo;) issued a press release, announcing Findings from Intranasal
Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form&nbsp;6-K. The information in the attached Exhibits 99.1 is
being furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934,
or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall
be expressly set forth by specific reference in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TIZIANA LIFE SCIENCES LTD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 27, 2023</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT&nbsp;INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0pt; border-bottom: Black 1.5pt solid; width: 9%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="padding: 0pt; width: 1%; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; border-bottom: Black 1.5pt solid; width: 90%; text-align: center; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0pt; vertical-align: top; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; vertical-align: top; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; vertical-align: top; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding: 0pt; vertical-align: bottom; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; vertical-align: top; text-indent: 0pt"><A HREF="ea177504ex99-1_tizianalife.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">News Service Announcement, dated April 27, 2023</FONT></A></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea177504ex99-1_tizianalife.htm
<DESCRIPTION>NEWS SERVICE ANNOUNCEMENT, DATED APRIL 27, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><B>Exhibit 99.1</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><IMG SRC="ex99-1_001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 24pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt">Tiziana
Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of
Neurology Conference</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no effective treatments for intracerebral hemorrhage (ICH), which has a 30% to 40% mortality rate</FONT></TD>
</TR></TABLE>

<P STYLE="margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal
anti-CD3 mAb treatment showed a reduction in Intracerebral Hemorrhage injury severity</FONT></TD>
</TR></TABLE>

<P STYLE="margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal
foralumab could represent a novel therapeutic approach for treating ICH and potentially other types of acute brain injury</FONT></TD>
</TR></TABLE>

<P STYLE="margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEW
YORK,&nbsp;April 27, 2023 -- Tiziana Life Sciences Ltd.&nbsp;(Nasdaq: TLSA) (&ldquo;Tiziana&rdquo; or the &ldquo;Company&rdquo;), a biotechnology
company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced broad-based findings on
the utility of nasal anti-CD3 mAb in the treatment of intracerebral hemorrhage (ICH). The data using a mouse model of collagenase-induced
ICH was presented at the Annual American Academy of Neurology conference. The full presentation can be viewed at https://www.aan.com/MSA/Public/Events/AbstractDetails/52974
until May 14, 2023.</FONT></P>

<P STYLE="text-align: justify; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Howard
L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and Co-Director of the Ann Romney Center for Neurologic Diseases at
Brigham and Women&rsquo;s Hospital, a founding member of Mass General Brigham Healthcare System, stated, &ldquo;Intracerebral hemorrhages
are the deadliest form of acute stroke with early mortality ranging from 30% to 40%. It has been well demonstrated that microglial activation
and edema play a critical role in the morbidity and mortality of this devastating event.&rdquo;</FONT></P>

<P STYLE="text-align: justify; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saef
Izzy, M.D., MBCHB., Neurocritical Care faculty at Brigham and Women&rsquo;s Hospital and Assistant Professor of Neurology at Harvard
Medical School and presenter of the study at AAN, commented, &ldquo;Currently, there are no effective interventions for ICH. Our research
studied the effect of an intranasal anti-CD3 antibody in a mouse model of induced ICH. I believe that intranasal anti-CD3 represents
a novel therapeutic approach for treating ICH as well as potentially other types of acute brain injury.&rdquo;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
the study demonstrated that intranasal anti-CD3 antibody:<SUP>1</SUP></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduced
                                            ICH injury severity</FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improved
                                            motor coordination recovery</FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improved
                                            memory retention and functional recovery</FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
                                            hematoma resolution at 7 days after ICH</FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduced
                                            neuronal cell death at 7 days after ICH</FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduced
                                            BBB leakage at 3 days after ICH</FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduced
                                            microgliosis at 7 days after ICH</FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduced
                                            astrocytosis at 7 days after ICH</FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increased
                                            CD4+FoxP3+ and FoxP3+ IL10+ dependent Tregs at the site of hematoma at 7 days after ICH</FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increased
                                            anti-inflammatory and reduced pro-inflammatory cytokines at the site of hematoma at 7 days
                                            after ICH</FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upregulated
                                            microglial phagocytic transcriptomic profile at 7 days after ICH </FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modulated
                                            microglial and astrocyte transcriptomic inflammatory profile after ICH </FONT></TD></TR></TABLE>

<P STYLE="margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
comprehensive and consistent findings of Dr. Izzy&rsquo;s research strongly supports the promising role of intranasal foralumab, the
only fully human anti-CD3 monoclonal antibody (mAb), and its potential for broad applications in neuroinflammation, including the treatment
of acute ICH,&rdquo; said Gabriele Cerrone, Executive Chairman, Founder, and interim Chief Executive Officer of Tiziana. &ldquo;These
exciting findings may allow Tiziana to explore additional intranasal foralumab neuroinflammatory indications to help patients with unmet
needs and create further shareholder value&rdquo;.</FONT></P>

<P STYLE="text-align: justify; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Foralumab</B></FONT></P>

<P STYLE="text-align: justify; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activated
T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds
to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune
cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects.
Intranasal foralumab Phase 2 trials are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation
by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.<SUP>2</SUP></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP>https://www.aan.com/MSA/Public/Events/AbstractDetails/52974</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
</SUP>https://www.pnas.org/doi/10.1073/pnas.2220272120</FONT>
</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About&nbsp;Tiziana
Life Sciences</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiziana
Life Sciences&nbsp;is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery
technologies to enable alternative routes of immunotherapy. Tiziana&rsquo;s innovative nasal approach has the potential to provide an
improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery.&nbsp; Tiziana&rsquo;s lead candidate,
intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in
patients in studies to date. Tiziana&rsquo;s technology for alternative routes of immunotherapy has been patented with several applications
pending and is expected to allow for broad pipeline applications.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further inquiries:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tiziana
Life Sciences Ltd</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Spencer, Business Development and Investor Relations<BR>
+44 (0) 207 495 2379<BR>
email:&nbsp;info@tizianalifesciences.com</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investors:</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>Irina
Koffler<BR>
LifeSci Advisors, LLC<BR>
+1 646 970 4681<BR>
ikoffler@lifesciadvisors.com</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"></P>


<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  B )8# 2(  A$! Q$!_\0
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M2EOHKF*^.H--?QV#Z6B6[:C-\!^'_P#@BA_P4H_83^(?QJOO^"1O_!13X?\
MPE^!OQT^(FJ?%+7/@3^TA\(-+\<V7A+Q7K<LJWLF@>+AX8\;W%_%:Z?#IFEV
M-T-"\/:C<Z7865GKUQK%UIZ:G=_JWX9^-_QUT']OSQ1\,/VB/&WC3X6?#GQ=
MXOO=#_9&\'Z5\+/!FI_ /X^>#;?X06'B.Z@U3XZKIVL^./#O[1FD>+=)^)^N
MWWPTUO6O FG7_@GPAIMQX3T+Q;:SZGJXW]>\=?M!_M#_ +7/QY^ ?PJ^-S?L
MV_#[]ESP?\&KCQ)JWA[X=^!_'GQ+^*?Q ^-6C^(/%]E<K/\ $S3/$GA;PW\*
M?"?AK0['2;?^RO"\WB3Q?XRO/%ML?$N@V7@^.UU97?Y+RT#E7GNW=.SN][,_
M,)OV5/\ @Z*O5:SNO^"G_P"PUIEM= V]QJ.E_L[6$^I6,,HV275A!=? Z&VE
MO(4)>W2>6*-I0NZ1!\PYOP]_P;T^,/ /_!)G]M']B+1/VD],^(G[4'[;/Q$T
M+XP_%#X[^/?#NI:%X&NO'.D^./"'BM]-@T'19-=UVSTB:WT#6#-K,AU+4[W7
M_$%UJ<NG6VGI;:/:?NM\;/BGXY^'_P ;?V*?A_H>IV3:%\9/BI\1?!WQ%-WI
M5K-=ZOI/A?\ 9U^*OQ"TTZ?-E?[&N/\ A*_"6C7L\MFI\RUCGL,""=Z^//BO
M^T1\>5_X*3+^SOX=\1?M"Z;\)]%^&?[,GBQK;X(_L\_#KXG>";;6?BC\1?CC
MHOBZX^/GQ,\7:=J&N_#?PO>Z/\.M M]&N/#@M;B'3X/%FK1SBZLH=I=^2]$E
ML'*O-Z-:MNU]['WA^R3\&=5_9S_99_9P^ &NZUI_B36O@E\#?A5\*-7\0Z3;
M7%GI>N:G\/\ P1HGA:_U;3;6\9KNWL-0NM+ENK2&Y8W$=O+&LW[P,*_/#_@N
M!_P32^(__!4[]E'P!\ ?A=\1_!/PR\1^#?VA_A_\8KC6_'MAKM_HE[HOACP_
MXV\.:II<*^'H+J^BU0Q^,$U*QWV[6MT^G/I]Q/8B\%_;=9^W3^V1\;OV6OVI
M_P!FD>&-.TGQ'^S+9?!OX^?&#]K[PZFAM?>.-)^%G@SQY^S[\/8_B]X*U2W\
MR]2'X(7/Q:G^(7C_ ,-PVEV?$/PST[QA<VB)K&B:46M67[<'Q'\+_P#!,#QU
M^V7J*>"_B!\1-"N_C1:>$IKF1/#_ ,.-6FL?VD/&OP@^%.L>(-0T5V%KX"T_
M28_">L>+->TZ9)+OPU9:KK4%U!+<"XC+V=^O]?YL=E:W2UCYH_;^_P""/'QG
M^-/[5GPK_P""A'["G[7ES^R;^V?\,OA?9?!V^UCQ/X'TSXB?"_X@^!+!-36W
ML=9T#4(KTZ1=RQZM>66IO+I7BC3-1L4TUTTFPU32X]2N?$?^&7O^#I'C_C9C
M^P6>G_-OEOS]<? H=>^,>V*_=[X$?#3XX?#^WU.;XU?M):O\?]6UBRTAFAN/
MAA\./AIX<\,:S;K<'67\':?X+TJ+74T#4I)H5L],\9^)O&FK:;;V4 ?Q%>W$
MMW<3_"W_  3T_:'^.WQ[^)WQMG^*6O\ [0M_H/AKXC_M+>$_#MKXC_9Z^'?@
M+]FPZ3\-OVE_&/PQ\'Q_"_XPZ+8#QM\0/$&G>$_#5I:ZK%K>I26]Y>CQ->RV
MXFTVVV%WY/U28N5=VO1M'Y@^%_\ @WA^,O[6/[07B']I_P#X+*_M?Z=^U;X^
M?X6:7\*_ ?@OX'^#+?X4^#_ ^DZ?XA'B".Y@U.'2=&CN8K::75U@TZU\%Z:]
M[>>)-6U75M3O+F*S12ON?XU_MJ^,_P!FO]H+XS?\-Q_M.:Q^Q+\%I_%R:/\
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2#Q-XALX+B.WUK4H[DHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
